Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

GenEdit, a US-based genetic medicine developer based on research at University of California (UC), Berkeley, has completed a $26m series A round featuring the UC-aligned venture capital fund Bow Capital. The round also included pharmaceutical firm Eli Lilly, conglomerate SK, KTB Network, Company K Partners, Korea Investment Partners, Dayli Partners, KB Investment, IMM Investment, TimeFolio Asset Management, DCVC Bio and Sequoia Capital. The spinout had raised $8.5m in a 2018 seed round co-led by SK and DCVC Bio that included Bow Capital and Sequoia Capital – both billed as existing backers.
EarthOptics, a US-based soil sensor developer exploiting research from Massachusetts Institute of Technology (MIT), has raised $10.3m in a series A round led by pharmaceutical and chemical producer Bayer’s investment arm Leaps by Bayer. The round also attracted S2G Ventures, Middleland Capital’s VTC Ventures fund, FHB Ventures and Route 66 Ventures, all of which were identified as existing…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).